Published Technical Disclosure Archive

Synergistic DNA Vaccines Against COVID-19 with AI, IoT, Blockchain, and Advanced Materials

Publication ID: 24-11857621_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic DNA Vaccines Against COVID-19 with AI, IoT, Blockchain, and Advanced Materials,” Published Technical Disclosure No. 24-11857621_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857621_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,621.

Summary of the Inventive Concept

The present disclosure combines synthetic pDNA vaccines against COVID-19 with AI-based diagnostics, IoT-enabled wearables, blockchain-based tracking, and advanced biodegradable materials to create a powerful, integrated system for preventing SARS-CoV-2 infection and monitoring immune responses.

Background and Problem Solved

The original patent disclosed synthetic pDNA vaccines against COVID-19, but it had limitations in terms of detection, monitoring, and distribution. The present inventive concept addresses these limitations by integrating the patented DNA vaccine with distinct technologies to create a more comprehensive and effective system.

Detailed Description of the Inventive Concept

The new system comprises a DNA vaccine of claim 1, which is engineered to express a SARS-CoV receptor binding domain, and an AI-based diagnostic tool trained on a dataset of SARS-CoV-2 genomic sequences. The system further includes a blockchain-based tracking system for monitoring vaccine distribution and administration. Additionally, the system may include an IoT-enabled wearable device for monitoring the subject's immune response. The DNA vaccine can be administered orally using a composite material comprising the DNA vaccine and a biodegradable polymer.

Novelty and Inventive Step

The new claims introduce the synergistic combination of the patented DNA vaccine with AI, IoT, blockchain, and advanced materials, which is not obvious from the original patent. The integration of these distinct technologies creates a new, more powerful system that is not anticipated by the prior art.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include using different AI algorithms for diagnostic analysis, incorporating additional IoT devices for real-time monitoring, or utilizing other biodegradable materials for oral administration. Variations may also include adapting the system for other infectious diseases or integrating with existing healthcare infrastructure.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the healthcare and biotechnology industries, particularly in the areas of vaccine development, disease diagnosis, and digital health. The system's integrated approach can provide a competitive advantage in the market, and its adaptability to other diseases and applications can ensure long-term growth and revenue.

CPC Classifications

SectionClassGroup
A A61 A61K39/215
A A61 A61K9/0019
A A61 A61P31/14
C C07 C07K14/005
A A61 A61K2039/53
A A61 A61K2039/54
A A61 A61K2039/545
C C12 C12N2770/20022
C C12 C12N2770/20034
C C12 C12N2770/20071

Field of Art

Biotechnology and molecular medicine, specifically vaccine design, genomic engineering, and infectious disease prevention, with expertise in DNA vaccine development, AI-driven diagnostics, and advanced drug delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in biotechnology or molecular biology, proficient in genetic engineering techniques, bioinformatics, vaccine design, and emerging digital health technologies, with knowledge of interdisciplinary approaches to infectious disease management

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with DNA vaccine platforms represents a predictable and logical extension of existing vaccine development strategies. The combination of AI diagnostics, blockchain tracking, and IoT monitoring with a known DNA vaccine design follows established trends in precision medicine and digital health innovation. The technical elements disclosed in the PTD represent incremental improvements that would be obvious to a skilled practitioner seeking to enhance vaccine efficacy and monitoring capabilities.

Obvious Combinations & Variations

Source Patent Element
DNA vaccine targeting SARS-CoV receptor binding domain
PTD Variation
AI-based diagnostic tool trained on SARS-CoV-2 genomic sequences
Obviousness Reasoning
Integrating computational diagnostics with vaccine technology is a known technique in precision medicine, representing a predictable application of machine learning to infectious disease management
Source Patent Element
Synthetic plasmid DNA vaccine design
PTD Variation
Blockchain-based tracking system for vaccine distribution
Obviousness Reasoning
Supply chain management and tracking technologies are well-established in pharmaceutical distribution, making their application to vaccine delivery an obvious design choice
Source Patent Element
DNA vaccine with specific genomic sequences
PTD Variation
IoT-enabled wearable device for monitoring immune response
Obviousness Reasoning
Personalized health monitoring through wearable technologies is a predictable extension of precision medicine approaches, representing a finite and obvious solution for tracking vaccine effectiveness
Source Patent Element
Oral administration potential for DNA vaccines
PTD Variation
Composite material with biodegradable polymer for oral delivery
Obviousness Reasoning
Developing alternative drug delivery mechanisms using biodegradable polymers is a known technique in pharmaceutical engineering, representing a predictable optimization of vaccine administration
Source Patent Element
SARS-CoV receptor binding domain targeting
PTD Variation
Machine learning algorithms for personalized vaccine recommendations
Obviousness Reasoning
Applying computational analysis to personalize medical interventions is a well-established approach in precision medicine, representing an obvious technological integration
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this publication would have been obvious to a person having ordinary skill in the art at the time of invention, as taught by US Patent 11857621. The incremental technological combinations represent predictable applications of known techniques in vaccine design, digital health, and precision medicine, thereby rendering potential patent claims obvious and anticipatable by the prior art.

Original Patent Information

Patent NumberUS 11,857,621
TitleSynthetic pDNA vaccines against COVID-19
Assignee(s)Imam Abdulrahman Bin Faisal University